No idea about specific timelines or prices. Too many things that are possible. The milestones that have been communicated for 2014, if achieved, would most certainly get AMBS beyond .40 in my opinion. How far beyond. Who knows. I think Lympro data alone and the promise of revenue in the very near future can be very close to achieving that price. A JV partner takes it way beyond....